Engaging plasticity: Differentiation therapy in solid tumors

14Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Cancer is a systemic heterogeneous disease that can undergo several rounds of latency and activation. Tumor progression evolves by increasing diversity, adaptation to signals from the microenvironment and escape mechanisms from therapy. These dynamic processes indicate necessity for cell plasticity. Epithelial-mesenchymal transition (EMT) plays a major role in facilitating cell plasticity in solid tumors by inducing dedifferentiation and cell type transitions. These two practices, plasticity and dedifferentiation enhance tumor heterogeneity creating a key challenge in cancer treatment. In this review we will explore cancer cell plasticity and elaborate treatment modalities that aspire to overcome such dynamic processes in solid tumors. We will further discuss the therapeutic potential of utilizing enhanced cell plasticity for differentiation therapy.

Cite

CITATION STYLE

APA

Bar-Hai, N., & Ishay-Ronen, D. (2022, August 11). Engaging plasticity: Differentiation therapy in solid tumors. Frontiers in Pharmacology. Frontiers Media S.A. https://doi.org/10.3389/fphar.2022.944773

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free